1Wu long,Lu Daopei.Blood and marrow transplantation in the People's Republic of China[J].Bone Marrow Transplant,2008,42(S1):S73 -75.
2Gluckman E,Rocha V,Boyer-Chammard A,et al.Outcome of cord-blood transplantation from related and unrelated donors[J].N Engl J Med,1997,337(6):373-381
3Lu Daopei.Blood and marrow transplantation in the People' s Republic of China[M]//Cecka JM,Terasaki PI.Clinical Transplants.Los Angeles: UCLA Immungenetics Center,2005:225 -228.
4Dey BR,SpitzerTR.Current status of haploidentical stem cell transplantation[J].Br J Haematol,2006,135(4):423 -437.
5Powles RL,Morgenstem CR,Kay HE,et al.Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia[J].Lancet,1983,1(8325):612-615.
6Mehta J,Singhal S,Gee AP,et al.Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia;ingle-center experience of 201 patients[J].Bone Marrow Transplantation,2004,33(4):389 -396.
7Waller EK,Giver CR,Rosenthal H,et al.Facilitating T-cell immune reconstitution after haploidentical transplantation in adults[J].Blood Cells Mol Dis,2004,33(3):233 -237.
8Guinan EC,Boussiotis VA,Neuberg D,et al.Transplantation of anergic histoincompatible bone marrow allografts[J].N Engl J Med,1999,340(22):1704-1714.
9Lu Daopei,Dong Lujia,Wu Tong,et al.Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation[J].Blood,2006,107(8):3065-3073.
10Lang P,Greil J,Bader P,et al.Longterm outcome after haploidentical stem cell transplantation in children[J].Blood Cells Mol Dis,2004,33(3):281 -287.
二级参考文献12
1Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med, 1993, 328: 593-602.
2Beatty PG. Marrow transplantation using volunteer unrelated donors in a comparison of mismatched family donor transplants:a Seattle perspective. Bone Marrow Transplant, 1994, 14 Suppl 4: S39-41.
3Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med,1998, 339: 1186-1193.
4Mineishi S, Longo WL, Atkinson ME, et al. Addition of highdose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Bone Marrow Transplant, 1999, 23: 1217-1222.
5Hassan HT,Stockschlader M,Schleimer B,et al. Comparison of the content and subpopulation of CD3 and CD34 positive cells in bone marrow harvest and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transplant Immunol, 1996,
6Mielcarek M, Roecklein BA, Torok-Storb B. CD14+- cells in GCSF mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma. Blood,1996, 87: 574-580.
7Pan L, Delmonte J Jr, Jalonen CK, et al. Pretreatment of donor mice with granulocyte-colony stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood, 1995,86 :
8Arpinati M, Loken M, Anasetti C. G-CSF mobilizes type 2-derdritic cells rather than type 1-dendritic cells. Blood, 1998, 92Suppl 1: 111a.
9Ji SQ, Chen HR, Wang HX, et al. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biol Blood Marrow Tran
10Ji SQ, Chen HR, Xun CQ, et al. The effect of G-CSF stimulated donor marrow on engraftment and incidence of graft-versushost disease in allogeneic bone marrow transplantation. Clin Transplant, 2001, 15: 317-323.
10Gratwohl A,Baldomero H,Frauendorfer K,et al.Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation:focus on increasing use of unrelated donors.Bone Marrow Transplant,2007,39:71-87.
